5 Best German Stocks to Buy Now

2. BioNTech SE (NASDAQ:BNTX)

BioNTech SE (NASDAQ:BNTX) is a German biotechnology company that develops and commercializes immunotherapies for cancer and other infectious diseases. As of August 3, the stock has a trailing twelve-month PE ratio of 3.53 and free cash flows of EUR 5.06 billion.

Wall Street is bullish on BioNTech SE (NASDAQ:BNTX). On July 11, H.C. Wainwright analyst Robert Burns revised his price target on BioNTech SE (NASDAQ:BNTX) to $283 from $298 and reiterated a Buy rating on the shares. On July 13, SVB Securities analyst Daina Graybosch upgraded BioNTech SE (NASDAQ:BNTX) to Outperform from Market Perform and reiterated her $223 price target.

At the close of Q1 2022, 29 hedge funds were long BioNTech SE (NASDAQ:BNTX) and held stakes worth $409.02 million in the company. This is compared to 27 positions in Q4 2021 with stakes worth $644.54 million.

In the first quarter of 2022, D E Shaw raised its stakes in BioNTech SE (NASDAQ:BNTX) by 114%, bringing them to $102.96 million. As of March 31, D E Shaw owns roughly 0.60 million shares of BioNTech SE (NASDAQ:BNTX) and is the largest shareholder in the company.